Skip to main content
Premium Trial:

Request an Annual Quote

Genomind, Emory Partner to Commercialize Alzheimer's Test

NEW YORK (GenomeWeb News) – Genomind today announced a partnership with Emory University to commercialize a blood-based screening test for mild cognitive impairment and Alzheimer's disease.

Under the terms of the deal, Genomind has attained the exclusive rights to commercialize blood-based protein biomarkers for assessment of the conditions. Other terms of the agreement were not disclosed.

"The development of this test represent one of the most significant efforts to date in making available a simple screening tool for mild cognitive impairment and Alzheimer's disease," Jay Lombard, chief scientific officer and medical director of Genomind, said in a statement. "But even more importantly, this joint effort between Genomind and Emory will allow us to consider preventive approaches for those at highest risk of developing Alzheimer's disease."

According to the Chalfont, Pa.-based company, more than 5 million Americans live with Alzheimer's, which is the sixth leading cause of death in the US.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.